WHO WE ARE

Our company focuses on research, development and manufacture of a blood-based diagnostic procedure for Alzheimer’s Disease.

Our goal is to make the early and reliable diagnosis of AD a reality with the use of a simple blood test.

The earlier the diagnosis of Alzheimer’s Disease, the better the chance of slowing down the process.

Structural Changes

AD shrinks the brain.

As AD spreads through the brain, connections between neurons and later the neurons themselves are lost. In the later stages, the brain noticeably shrinks.

How AD develops

A vicious cycle of plaque deposits, neuronal death and inflammation.

Amyloid plaque deposition is a hallmark of AD and amyloid acts together with Tau leading to neurodegnerative processes. Amyloid itself may not be sufficient to induce neurodegeneration, but rather triggers inflammatory processes that need to be balanced.

Microscopic Changes

In the early stages, only microscopic changes are visible.

Two important factors, amyloid beta peptide deposits and neurofibrillary tangles caused by tau-proteins are only visible under a microscope.

Structural Changes

AD shrinks the brain

As AD spreads through the brain, connections between neurons and later the neurons themselves are lost. In the later stages, the brain noticeably shrinks.

Microscopic Changes

In the early stages, only microscopic changes are visible

Two important factors, amyloid beta peptide deposits and neurofibrillary tangles caused by tau-proteins are only visible under a microscope.

How AD develops

A vicious cycle of plaque deposits, neuronal death and inflammation.

Amyloid plaque deposition is a hallmark of AD and amyloid acts together with Tau leading to neurodegnerative processes. Amyloid itself may not be sufficient to induce neurodegeneration, but rather triggers inflammatory processes that need to be balanced.

Dispelling a few myths about AD.

AD is not dementia


It's a specific cause of dementia.

Dementia is not the same as AD. Dementia is a broad term, describing a decline in cognition that has significant impact on everyday activities. Dementia has different causes, some of which are reversible.

It is important to distinguish AD from dementia.

AD is a disease and only one possible cause of dementia.

AD is a disease


Early diagnosis is important.

It can therefore be specifically diagnosed or ruled out. Excluding AD as a diagnosis can be very helpful.

AD clinically starts with only subtle cognitive deficits and can develop to dementia within years. As with most diseases, early diagnosis is important.

The earlier it´s diagnosed, the more options you have.

AD can be treated


Patients can get help.

Even without disease modifying treatment available yet, there is a number of therapeutic measures available to help patients. It is also important to remember the impact on families and carergivers, who also benefit from treatment.

Changes in lifestyle can possibly lengthen the period of time before AD becomes detrimental.

Dementia is our most feared illness.
More than heart disease or cancer.

David Perlmutter

Renowned neurologist and author

Most people want to know.

82

82 %

%

would take
a genetic test
to know their risk

would take a genetic test
to know their risk

As society ages and AD prevalence grows, so does the demand for simple and reliable testing at scale.

As the population in industrial countries is aging, the total number of people at risk to develop AD will increase, since old age is by far the biggest risk factor for AD.

The ethics question

No sh*tstorms please.

Not everyone will want to know. And that's okay for us. But we do think everyone should have the choice.

While not everyone will want to know if he or she suffers from AD, those who want to know should get the chance for a readily available test.

There are no simple & reliable diagnostic tests for AD available.

Current tests require extraction of cerebrospinal fluid (CSF) in a specialized center or hospital.


Diagnostic methods via positron emission tomography (PET), magnetic resonance imaging (MRI) and lumbar puncture are invasive and expensive.


The current tests are based on the amyloid hypothesis. This most likely excludes a number of factors that determine the clinical manifestation of AD.

The new era of AD diagnostics presented by Predemtec.

We developed a testing method to detect the presence of AD from a simple blood sample.

Our approach

We identified seven blood biomarkers that reliably diagnose AD.

The biomarkers are cytokines and growth factors which have been selected based on their involvement in neuroprotective or neurodegenerative processes or based on their general association with the immune system in neurological diseases, specifically with AD.

How it works

Our biomarkers enable a simple four-step detection process.

Step 1

A small amount of blood is drawn at your family doctor‘s office.

Step 2

Our assays quantify the biomarkers.

Step 3

Our algorithm identifies relationships and values.

Step 4

The results are made easy for the doctor to interpret.

Patent approved

Biomarker and Methods for early diagnosis of Alzheimer´s disease

International publication WO 2015/113995 A1 | European patent Nr. 3102950

Valid in: Austria, Belgium, Switzerland, Czech Republic, Germany, Denmark, Spain, France, Great Britain,
Hungary, Ireland, Italy, Netherlands, Poland, Sweden, Slovenia, Slovakia | Israel | Russia | China | USA

 

Predemtec can deliver maximum reliability at scale with a simple blood test.

OUR TEAM

Dr. Carola Schipke

Chief Scientific Officer

More than 10 years experience in biomarker development in the field of neurodegenerative diseases, also in clinical settings, fundamental research and method development for biomarker-based diagnostic approaches in neurology and psychiatry. Author on more than 30 peer-reviewed publications, more than 15 as first or last author.

Dipl.-Psych. Felix Menne

Clinical Trial Manager

Stephanie Göhler

Technician

Dipl.-Ing. Raúl Galindo

Interim CEO

Dipl.-Kfm. Sebastian Müller-Potthoff

CFO

Dipl.-Ök. Heike Röllinghoff

Office

OUR TEAM